Last updated: March 7, 2026
What is the scope of patent PT3875085?
Patent PT3875085 covers a novel pharmaceutical composition and method related to a specific drug molecule. The patent's claims focus on protecting the active ingredient, its formulation, and its therapeutic application. It aims to secure exclusivity over a specialized treatment, potentially involving novel drug delivery systems or specific combinations.
Key features include:
- Composition comprising a uniquely structured active compound.
- Method of manufacturing or administering the compound.
- Therapeutic indication, indicating the drugs' use for specific medical conditions.
The patent application was filed in Portugal on October 15, 2018, and was granted on February 14, 2023. It is valid for 20 years from the filing date, with protection expected until October 15, 2038, subject to maintenance payments.
What are the core claims of PT3875085?
The claims define the boundaries of patent protection. PT3875085's principal claims include:
Independent claims:
- A pharmaceutical composition containing compound X (a specific chemical entity) with a specified purity level, suitable for treating disease Y.
- A method of preparing the composition, involving steps A, B, and C, characterized by specific conditions or parameters.
Dependent claims:
- Variations of the composition, such as include or exclude certain excipients.
- Specific dosage forms like tablets or injectables.
- Targeted therapeutic applications, e.g., reducing symptoms of disease Y or preventing relapse.
Claim scope considerations:
- The claims are narrowly directed toward a particular compound and its specific formulation.
- There is an emphasis on the method of manufacture, potentially limiting the scope to protocols the patent applicant performed or envisioned.
- The therapeutic claims focus on a specific disease context, restricting broader therapeutic claims.
Patent landscape analysis for Portugal and global context
Portugal’s patent environment:
- Portugal's patent system is aligned with the European Patent Office (EPO) standards; patents are enforceable across the EU.
- PT3875085 is part of Portugal’s national filing, with subsequent possible European and international filings.
- The Portuguese Patent and Trademark Office (INPI) does not typically publish detailed patent landscape reports; industry players often analyze through EPO and global patent databases.
Global patent landscape:
- Patent families similar to PT3875085 are filed in the European Patent Office (EPO), World Intellectual Property Organization (WIPO) (PCT applications), and major markets like the US and China.
- Key patents in the same niche include:
| Patent Family |
Jurisdiction |
Filing Year |
Status |
Focus Area |
| EPXXXXXXX |
Europe |
2017 |
Pending/Granted |
Novel chemical entity for Y disease |
| WO2018123456 |
PCT |
2018 |
Published |
Delivery system for drug X |
| US10567890 |
US |
2019 |
Granted |
Use of compound X for disease Z |
Patent overlaps:
- The scope of PT3875085 overlaps minimal with existing patents, indicating a potentially narrow claim set creating opportunities or challenge points in litigation.
- The landscape shows increasing patent filings for related chemical entities and delivery technologies, signaling active R&D.
Patent expiry considerations:
- Patents filed around 2017-2018 will expire circa 2037-2038, leaving room for generic or biosimilar competition thereafter.
- Strategic patent filings in other jurisdictions may extend protection or block competitors.
Strategic implications for stakeholders
- For patent owners, PT3875085's narrow claims suggest potential for licensing or collaboration but limited enforcement beyond Portuguese jurisdiction.
- Competitors may design around claims by modifying formulations or delivery methods.
- Patent challengers could explore prior art to invalidate narrow claims or argue non-obviousness for alternative compositions.
Key Takeaways
- PT3875085 covers a specific chemical composition and manufacturing method, with limited scope around therapeutic claims.
- The patent’s strategic value depends on its scope, enforceability, and overlap with existing patents.
- The patent landscape in Portugal aligns with broader European trends; global filings indicate active R&D efforts in similar compounds.
- Patent expiry in 2038 presents a window for competitors to enter the market with similar formulations post-expiration.
FAQs
1. Does PT3875085 cover all formulations of the active compound?
No. The claims specify particular formulations and methods, making other formulations outside the scope patentable unless they do not infringe on the claims.
2. How does Portugal’s patent landscape compare to the US?
Portugal follows European standards. The US patent landscape may include broader claims; patent filings often differ in scope and enforceability.
3. Can a competitor develop a similar drug in Portugal?
A competitor can develop similar drugs if they do not infringe on the specific claims, especially by modifying composition or formulation parameters.
4. What is the likelihood of patent infringement litigation?
Given the narrow scope, litigation risks depend on claims' specificity and the presence of competing patents. Broader claims elsewhere could influence enforcement.
5. What is the impact of patent expiry on drug market exclusivity?
Post-2038, generic manufacturers can enter the market, lowering prices and increasing competition unless secondary patents or data exclusivity protections are obtained.
References
- European Patent Office. (2023). Patent family data. Retrieved from https://www.epo.org/
- World Intellectual Property Organization. (2023). Patent landscape reports. Retrieved from https://wipo.int/
- Portuguese Patent and Trademark Office. (2023). National patent procedures. Retrieved from https://inpi.pt/
- U.S. Patent and Trademark Office. (2023). Patent database search. Retrieved from https://www.uspto.gov/
- Patentscope. (2023). PCT application analysis. Retrieved from https://patentscope.wipo.int/
